Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Diez-Perez, A; Naylor, KE; Abrahamsen, B; Agnusdei, D; Brandi, ML; Cooper, C; Dennison, E; Eriksen, EF; Gold, DT; Guañabens, N; Hadji, P; Hiligsmann, M; Horne, R; Josse, R; Kanis, JA; Obermayer-Pietsch, B; Prieto-Alhambra, D; Reginster, JY; Rizzoli, R; Silverman, S; Zillikens, MC; Eastell, R; Adherence Working Group of the International Osteoporosis Foundation and the European Calcified Tissue Society.
International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.
Osteoporos Int. 2017; 28(3):767-774
Doi: 10.1007/s00198-017-3906-6
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Obermayer-Pietsch Barbara
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Adherence to oral bisphosphonates is low. A screening strategy is proposed based on the response of biochemical markers of bone turnover after 3 months of therapy. If no change is observed, the clinician should reassess the adherence to the treatment and also other potential issues with the drug. Low adherence to oral bisphosphonates is a common problem that jeopardizes the efficacy of treatment of osteoporosis. No clear screening strategy for the assessment of compliance is widely accepted in these patients. The International Osteoporosis Foundation and the European Calcified Tissue Society have convened a working group to propose a screening strategy to detect a lack of adherence to these drugs. The question to answer was whether the bone turnover markers (BTMs) PINP and CTX can be used to identify low adherence in patients with postmenopausal osteoporosis initiating oral bisphosphonates for osteoporosis. The findings of the TRIO study specifically address this question and were used as the basis for testing the hypothesis. Based on the findings of the TRIO study, specifically addressing this question, the working group recommends measuring PINP and CTX at baseline and 3 months after starting therapy to check for a decrease above the least significant change (decrease of more than 38% for PINP and 56% for CTX). Detection rate for the measurement of PINP is 84%, for CTX 87% and, if variation in at least one is considered when measuring both, the level of detection is 94.5%. If a significant decrease is observed, the treatment can continue, but if no decrease occurs, the clinician should reassess to identify problems with the treatment, mainly low adherence.
- Find related publications in this database (using NLM MeSH Indexing)
- Administration, Oral -
- Biomarkers - blood
- Bone Density Conservation Agents - administration & dosage
- Bone Density Conservation Agents - therapeutic use
- Bone Remodeling - physiology
- Collagen Type I - blood
- Diphosphonates - administration & dosage
- Diphosphonates - therapeutic use
- Drug Evaluation, Preclinical - methods
- Drug Evaluation, Preclinical - standards
- Female -
- Humans -
- Medication Adherence -
- Osteoporosis, Postmenopausal - drug therapy
- Peptide Fragments - blood
- Peptides - blood
- Procollagen - blood
- Find related publications in this database (Keywords)
- Adherence
- Bisphosphonates
- Osteoporosis treatment
- Position paper
- Screening